Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcadia Biosciences's ROE % for the quarter that ended in Mar. 2026 was -503.05%. Arcadia Biosciences's PB Ratio for the quarter that ended in Mar. 2026 was 3.07.
Arcadia Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -163.86%.
Arcadia Biosciences ROE % Adjusted to Book Value Related Terms
Arcadia Biosciences ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Arcadia Biosciences's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcadia Biosciences ROE % Adjusted to Book Value Chart
FRA:17D vs ORISF, ARRT, CIMG: ROE % Adjusted to Book Value Comparison
For the Packaged Foods subindustry, Arcadia Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences ROE % Adjusted to Book Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -163.86% mean?
Arcadia Biosciences (FRA:17D) has a ROE % Adjusted to Book Value of -163.86% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Arcadia Biosciences and its competitors.
Is Arcadia Biosciences' ROE % Adjusted to Book Value too high?
Arcadia Biosciences' current ROE % Adjusted to Book Value is -163.86%. Overall, Arcadia Biosciences has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' ROE % Adjusted to Book Value compare to ORISF and ARRT?
Arcadia Biosciences' ROE % Adjusted to Book Value of -163.86% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Consumer Packaged Goods company?
A good ROE % Adjusted to Book Value depends on the Consumer Packaged Goods industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Arcadia Biosciences and its competitors. Arcadia Biosciences's current ROE % Adjusted to Book Value is -163.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Arcadia Biosciences (FRA:17D) has a current ROE % Adjusted to Book Value of -163.86%. The stock's GF Value™ is €15.09, compared to a current price of €3.72 — trading 75.3% below its estimated fair value. The current ROE % Adjusted to Book Value is -163.86%. Arcadia Biosciences' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Arcadia Biosciences (FRA:17D), the current ROE % Adjusted to Book Value is -163.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcadia Biosciences (FRA:17D) Overvalued in 2026?
Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued.
The current stock price of €3.72 is trading 75.3% below its estimated GF Value™ of €15.09.
Key valuation signals for FRA:17D:
ROE % Adjusted to Book Value: -163.86%
GF Value™: €15.09 vs. price of €3.72 (75.3% below fair value)
No single metric tells the full story. See the FRA:17D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for FRA:17D
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17D has been successfully added to your 
